Patenting Dolly

A rejected patent on Dolly the cloned sheep may have a broad impact on personalized medicine.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

I am a PhD molecular

I am a PhD molecular biologist and a patent agent. Why would we want a company granted a patent that could potentially own the patient (ie the "product" of a process such as future personalized medicine processes for example CRISPR correction of mutations that cause disease)? In my opinion the court ruled correctly in this case. The granted method patent should be enough to make profits.